Washington University School of Medicine

Digital Commons@Becker
2020-Current year OA Pubs

Open Access Publications

9-29-2020

Phenotypic diversity in an international Cure VCP Disease registry
Chiseko Ikenaga
Washington University School of Medicine in St. Louis

Andrew R Findlay
Washington University School of Medicine in St. Louis

Michelle Seiffert
Washington University School of Medicine in St. Louis

Allison Peck
Cure VCP Disease, Inc.

Nathan Peck
Cure VCP Disease, Inc.

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4
Part of the Medicine and Health Sciences Commons

Recommended Citation
Ikenaga, Chiseko; Findlay, Andrew R; Seiffert, Michelle; Peck, Allison; Peck, Nathan; Johnson, Nicholas E;
Statland, Jeffrey M; and Weihl, Conrad C, "Phenotypic diversity in an international Cure VCP Disease
registry." Orphanet Journal of Rare Diseases. 15, 1. 267 (2020).
https://digitalcommons.wustl.edu/oa_4/489

This Open Access Publication is brought to you for free and open access by the Open Access Publications at
Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized
administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors
Chiseko Ikenaga, Andrew R Findlay, Michelle Seiffert, Allison Peck, Nathan Peck, Nicholas E Johnson,
Jeffrey M Statland, and Conrad C Weihl

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/oa_4/489

(2020) 15:267
Ikenaga et al. Orphanet J Rare Dis
https://doi.org/10.1186/s13023-020-01551-0

Open Access

RESEARCH

Phenotypic diversity in an international Cure
VCP Disease registry
Chiseko Ikenaga1, Andrew R. Findlay1, Michelle Seiffert1, Allison Peck2, Nathan Peck2, Nicholas E. Johnson3,
Jeffrey M. Statland4 and Conrad C. Weihl1*

Abstract
Background: Dominant mutations in valosin-containing protein (VCP) gene cause an adult onset inclusion body
myopathy, Paget’s disease of bone, and frontotemporal dementia also termed multisystem proteinopathy (MSP). The
genotype-phenotype relationships in VCP-related MSP are still being defined; in order to understand this better, we
investigated the phenotypic diversity and patterns of weakness in the Cure VCP Disease Patient Registry.
Methods: Cure VCP Disease, Inc. was founded in 2018 for the purpose of connecting patients with VCP gene mutations and researchers to help advance treatments and cures. Cure VCP Disease Patient Registry is maintained by Coordination of Rare Diseases at Sanford. The results of two questionnaires with a 5-point Likert scale questions regarding
to patients’ disease onset, symptoms, and daily life were obtained from 59 participants (28 males and 31 females)
between June 2018 and May 2020. Independent of the registry, 22 patients were examined at the Cure VCP Disease
annual patient conference in 2019.
Results: In the questionnaires of the registry, fifty-three patients (90%) reported that they were with inclusion body
myopathy, 17 patients (29%) with Paget’s disease of bone, eight patients (14%) with dementia, two patients (3%)
with amyotrophic lateral sclerosis, and a patient with parkinsonism. Thirteen patients (22%) reported dysphagia and
25 patients (42%) reported dyspnea on exertion. A self-reported functional rating scale for motor function identified
challenges with sit to stand (72%), walking (67%), and climbing stairs (85%). Thirty-five (59%) patients in the registry
answered that their quality of life is more than good. As for the weakness pattern of the 22 patients who were evaluated at the Cure VCP Disease annual conference, 50% of patients had facial weakness, 55% had scapular winging, 68%
had upper proximal weakness, 41% had upper distal weakness, 77% had lower proximal, and 64% had lower distal
weakness.
Conclusions: The Cure VCP Disease Patient Registry is useful for deepening the understanding of patient daily life,
which would be a basis to develop appropriate clinical outcome measures. The registry data is consistent with previous studies evaluating VCP patients in the clinical setting. Patient advocacy groups are essential in developing and
maintaining disease registries.
Keywords: Cure VCP disease patient registry, Multisystem proteinopathy, Valosin-containing protein
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Background
Multisystem proteinopathy (MSP) is a rare inherited
disorder, which affect various organs including the
nervous system, skeletal and cardiac muscle, and bone
[1, 2]. Mutations in valosin containing protein (VCP),
HNRNPA1, HNRNPA2B1, and SQSTM1 genes have been
identified as cause of the disease [3–5]. Among these
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genes, the VCP gene was the first to be detected and its
disease-causing mutations account for the majority of
patients with this syndrome [6]. Clinically, phenotypes
of the VCP-related MSP are heterogeneous even within
families, including inclusion body myopathy, Paget’s disease of bone, and frontotemporal dementia [1, 2]. Other
phenotypes have been described as amyotrophic lateral
sclerosis (ALS), Parkinson’s disease, hereditary spastic
paraplegia, Charcot-Marie-Tooth disease, Facial-onset
sensory and motor neuronopathy, neuropathy, cardiomyopathy, and cataracts [2, 7–17]. However, few studies
inform the phenotypic presentation of VCP-related MSP
(VCP disease).
The estimated prevalence of the disease has been
reported as 0.66/100,000 population and yet information as to the natural history and phenotypic variability
with this expanding phenotype is limited because of the
rarity of the disease [18]. Specifically, there have been no
reports, which describe the patient experience of living
with VCP-related MSP. The Cure VCP Disease Patient
Registry was founded to accelerate the development of
the cure for this rare disease related to mutations of the
VCP gene. Since its foundation, the information including patient activity of daily life and quality of life (QOL)
has been obtained, which help understanding the varied
phenotypes of this disease.
In this article, we combined a retrospective registry
cohort, with a cross sectional observational study at the
Cure VCP Disease annual patient conference to identify
the burden of the disease and better define the phenotypic variability associated with VCP-related MSP.

Materials and methods
Organization and study design

Cure VCP Disease, Inc. is a patient advocacy organization formed to drive efforts to find a cure for VCPrelated MSP, founded in February 2018. The activities
are entirely volunteer led, including outreach to patients,
networking with researchers and drug companies,
expanding a patient registry, and building awareness in
the medical community. In June 2018, the Cure VCP Disease Patient Registry was created to assist in identifying
and collecting information about patients. The registry
is hosted through Coordination of Rare Diseases at Sanford (CoRDS), a centralized international patient registry
for rare diseases. In April 2019, the first Cure VCP Disease patient and caregiver conference was conducted at
Washington University in St. Louis.
In this study, we performed a cross-sectional observational study using questionnaires and the results of
patient assessments at the first Cure VCP Disease patient
conference.
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Participants and data collection
There were 59 participants, who were registered for the
Cure VCP Disease Patient Registry between June 2018
and May 2020. Among them, 54 patients were symptomatic and the other five participants were asymptomatic
carriers.
At the time of first registration, patients or their legally
authorized representative answered to a web-based 81
item questionnaire, which was designed to ask participants’ demographic information and symptoms (Additional file 1: Fig.S1). The information is updated annually.
They also took a survey of 69 questions regarding to their
mutation type, their diagnoses, how they evaluate their
QOL, and cognitive/bulbar/respiratory/truncal/upper
extremity/lower extremity functions (Additional file 2:
Fig.S2). QOL was rated on a 5-point Likert scale from
“poor” to “excellent.” A likert scale was also used to rate
function from “no difficulty” to “unable to do”.
Under an independent protocol from the CoRDS registry, 22 symptomatic patients attended the first Cure
VCP Disease patient conference in 2019. In the conference, we examined them as to their Medical Research
Council (MRC) scale, quantitative manual muscle testing using dynamometry, timed up and go test, Inclusion
Body Myositis Functional Rating Scale (IBMFRS), ALS
Cognitive Behavioral Screen (ALS-CBS), and Forced vital
capacity (FVC) [19–21].
Statistical analyses
We used Fisher’s exact test to compare categorical variables. For calculating Spearman’s rank correlation coefficient, we used R (version 3.6.1). We considered p values
less than 0.05 as statistically significant.
Results
Among the 59 participants registered, 57 participants
enrolled by themselves, while two participants were
enrolled by their legally authorized representatives for
cognitive reasons. Six participants preferred to update
their annual information by postal mail, whereas other
participants chose to update their information online.
Twenty-two patients completed questionnaires, functional tests, and physical exams at an annual patient
conference.
Demographics

The registry included participants from nine countries
(Fig. 1). The registry cohort had slightly more women and
94% were Caucasian (Table 1). Among the 33 patients
whose information of mutation types were available,
seven mutations (R93C, G125D, R155H, R155C, R159C,
R159H, and R191Q) were included.
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Table 1 Demographics
to the questionnaire

of

patients

who

answered
Total
participants
(n = 59)

Participant sex (M:F)

28:31

Age at onset (n = 41)a,b,c

42.4 ± 10.3

Age at onset of Paget’s disease (n = 13)a,b

48.2 ± 10.9

Age at onset of muscle weakness (n = 53)a,b
Age at onset of dementia (n = 7)a,b
Age at diagnosis (n = 55)a,b
Age at submissionb

b

Racial categories (n = 55)a

The reported phenotypes included 53 patients (90%)
diagnosed with inclusion body myopathy, 17 patients
(29%) with Paget’s disease of bone, eight patients (14%)
with dementia, six patients (10%) with peripheral neuropathy, four patients (7%, two patients were with R155H
or R191Q mutation in VCP gene) with cardiomyopathy, four patients (7%) with cataracts, two patients (3%)
with ALS, and one patient (2%) with Parkinson’s disease
(Fig. 1). There were five participants without any symptoms, however they had family history of VCP-related
MSP and confirmed their own VCP gene mutations.

46.6 ± 10.5
51.7 ± 11.1
52 (94%)

Asian

2 (4%)

Black or African American

1 (2%)

Hispanic or Latino

4 (9%)

Others

40 (91%)

Mutations in VCP gene (n = 33)a

Diagnoses

56.7 ± 12.5

Caucasian

Ethnicity (n = 44)a

Fig. 1 Demographic and phenotypes. Patients from nine countries
were registered. Fifty-three patients (90%) were diagnosed with IBM,
17 patients were (29%) with PDB, and eight patients (14%) were with
dementia. 1: Two patients were also with peripheral neuropathy. 2:
One patient was also diagnosed with cataract and another patient
was diagnosed with ALS, cataract, and peripheral neuropathy. 3: Four
patients were diagnosed with IBM and cardiomyopathy. One patient
was diagnosed with IBM and peripheral neuropathy. Another patient
was diagnosed with IBM, peripheral neuropathy, and cataracts.
Another patient was diagnosed with IBM and cataracts. Another
patient had IBM and Parkinson’s disease. The other patient was
diagnosed with IBM, ALS, and peripheral neuropathy. IBM inclusion
body myopathy, PDB Paget’s disease of bone, ALS amyotrophic lateral
sclerosis

40.4 ± 10.0

464G>A (R155H)

14 (42%)

463C>T (R155C)

6 (18%)

475C>T (R159C)

4 (12%)

277C>T (R93C)

3 (9%)

476G>A (R159H)

3 (9%)

572G>A (R191Q)

2 (6%)

374G>A (G125D)

1 (3%)

Values are no. (%) unless otherwise indicated
a

The number of patients in the parenthesis corresponded with that of patients
who answered to the questions

b
c

Mean ± SD, years

Age at onset refers to the age at onset of the first symptom

The age at first symptom was 42.4 ± 10.3 and there were
6.5 ± 7.5 from onset to diagnosis (mean ± SD, years).
There were 4.9 ± 5.0 (mean ± SD, years) from diagnosis
to submission of the questionnaire. The age at onset was
around forty on muscle weakness (39.0 ± 9.0 (mean ± SD,
years) in patients with R159C) and patients tended to
be present with Paget’s disease of bone in mid forty and
dementia in mid-fifty.
Cognitive function

There were 25 patients (42%), who had to read something
several times to understand it, 14 patients (24%) had difficulties in planning for and keeping appointments that
are not part of their weekly routine, and 16 patients (27%)
felt difficulties in learning new tasks or instructions more
than once per a week. In the annual Cure VCP Disease
conference in 2019, the average score of ALS-CBS was
17.1 out of 20.
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Bulbar, respiratory, and motor functions

Thirteen patients (22%) had experienced occasional
choking and one patient needed a modified diet. Seven
patients (12%) were also aware of their excessive saliva.
Six patients (10%) had detectable speech disturbances
and could be intelligible with repeating. Twenty-five
patients (42%) noticed their shortness of breath when
they were walking, eating, bathing, or dressing. Twelve
patients (21%) had orthopnea, seven patients (12%) used
some machine which support ventilation or supplementary oxygen, and two patients (3%) were not able to
sleep enough despite using extra pillows and ventilatory
support machines. Truncal, upper extremity, and lower
extremity functions were also assessed by asking their
activities in daily life (Fig. 2, Fig. 3).
Weakness distributions examined at the Cure VCP Disease
annual conference in 2019

Among the total 22 patients, who attended the Cure
VCP Disease annual conference in 2019, there were
11 patients (50%) with facial weakness and 12 patients
(55%) with scapular winging (Table 2). Patients had both
upper and lower proximal/distal limbs weakness with a
predominance of lower limbs weakness (Fig. 4). There
were fifteen patients (68%) with upper proximal weakness, nine patients (41%) with upper distal weakness,
17 patients (77%) with lower proximal weakness, and 14
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patients (64%) with lower distal weakness. The distribution of weakness was asymmetric in 12 (55%) patients.
Fourteen patients (64%) use walking aids including cane,
walker, and wheelchair (Table 2). As for the IBMFRS, the
score was 29.0 ± 7.0 (mean ± SD) out of 40 and the score
was below 2.5 in the following question: sit to stand,
walking, and climbing stairs, which refer to the lower
extremity weakness. The forced vital capacity was in the
range of 48%–70% of the predicted value in nine patients
(41%) (Table 2).
Quality of life

Thirty-five patients (59%) answered that their QOL was
either excellent (n = 4, 7%), very good (n = 15, 25%),
or good (n = 16, 27%). As for everyday physical activities and usual social activities, 31 patients (53%) and 32
patients (54%), respectively, answered that they can carry
out these activities completely/mostly/moderately. Mentally, 48 patients (81%) answered that they are in excellent/very good/good condition, although 36 patients
(63%) had been sometimes/often/always bothered by
emotional problems.
Compared with patients who have isolated muscle
weakness, patients with muscle weakness and dementia tended to answer that their QOL is fair or poor (7/26
vs. 6/8, p = 0.03), while patients with muscle weakness
and Paget’s disease of bone did not refer to significant

Fig. 2 Patients who felt difficulties in the activities of daily life involving upper extremities and trunk. We sent the questionnaire to 59 participants
and we were able to get replies from 53 to 58 patients on each question. The figure shows the percentage of patients who felt difficulties in the
activities of daily life involving upper extremities and trunk
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Fig. 3 Patients who felt difficulties in the activities of daily life involving lower extremities. We sent the questionnaire to 59 participants and we
were able to get replies from 53 to 58 patients on each question. The figure shows the percentage of patients who felt difficulties in the activities of
daily life involving lower extremities

difference as to QOL (7/26 vs. 9/17, p = 0.11). As for the
correlation between QOL and other functions, the Spearman’s rank correlation coefficient between QOL and the
answers of the following questions were 0.6; push open
a heavy door, bend down and pick up clothing from the
floor. However, there was no other question which has
stronger relevance with QOL than these two questions.
As for pain, patients with Paget’s disease of bone rated
their own pain as 3.4 ± 1.9 (“0” being no pain and “10”
being the worst pain imaginable, mean ± SD), while other
symptomatic participants rated their pain as 3.7 ± 2.5
(mean ± SD).

Discussion
In this study, we describe the physical, mental and social
burden on patient daily life in MSP with VCP gene mutations using data from a rare disease registry and in person patient conference. These data confirm several
features of VCP-related MSP that have been reported
by clinical studies. Specifically, as with previous cohorts,
there was no significant difference as to the distribution
among sexes and onset of symptoms was in the fourth
decade [1, 2]. Regarding the mutation type, the two most
common mutations were similar to a previous study [22].
The R155H mutation, which is the most common among
the patients, has been known to be associated with inclusion body myopathy, Paget’s disease of bone, frontotemporal dementia, and ALS [3, 7]. As for the R159C, which
was the third most common in this cohort, later age of
onset of myopathy and absence of Paget’s disease of bone

was suggested to have relevance [10, 22, 23]. Indeed,
there was no patient with Paget’s disease of bone among
those with R159C. The age at onset of myopathy was
39.0 ± 9.0 years old in patients with R159C, which was
different from the previous study [22].
As for the diagnoses, there was only two patient (3%)
who had all the findings of myopathy, Paget’s disease of
bone, and frontotemporal dementia. A previous study
also showed that patients with the full spectrum of the
disease have been reported to make up only 12% of
those affected, which suggest that physicians have to
make a diagnosis even though some typical clinical feature is lacking [1]. In addition, intrafamilial phenotype
variability was also reported, which means that even
the patients who have the same variants can present
different phenotypes [24]. Compared with a previous
clinical study, which described the percent of patients
with myopathy 90%, Paget’s disease of bone 42%, and
frontotemporal dementia 30%, the percent of patients
with dementia in this study was lower [22]. This may
be because patients with severe dementia were not
able to enroll themselves in this questionnaire-based
study. As for the cognitive score of the ALS-CBS, the
average score in normal controls was 15.67 ± 2.92
(mean ± SD, 50–59 years) and that in ALS patients was
reported to be 14.66 ± 3.54 (mean ± SD, 50–59 years),
while other reports that in ALS patients with frontotemporal dementia was 3.7 ± 3.4 in a previous report
(mean ± SD) [25, 26]. The average score of the ALSCBS in the Cure VCP Disease annual meeting was
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on

patients

Total participants (n = 22)
Participant sex (M:F)

10:12

Age at onset (n = 19)a

43.4 ± 8.9

Age at participationa

55.2 ± 9.9

Age at diagnosis (n = 17)a
Forced vital capacity, % predictedb (range)
ALS-CBSb,c (range)

49 ± 7.9

82 ± 25 (48–146)

17.1 ± 1.6 (14–20)

Facial weakness

11 (50%)

Weakness of eye closure

7 (32%)

Weakness of lip closure

9 (41%)

Scapular winging

12 (55%)

Bilateral

5 (23%)

Unilateral

7 (32%)

IBM-FRSb,d (range)
Timed up and go testb,e (n = 17, s, range)

29.0 ± 7.0 (9–39)

12.2 ± 6.0 (5.0–27.6)

Walking aid

14 (64%)

Cane

9 (41%)f

Walker

11(50%)g

Wheelchair

5 (23%)h

a
b
c

Mean ± SD, years
Mean ± SD

Amyotrophic Lateral Sclerosis Cognitive Behavioral Screen (ALS-CBS) is a
screening tool for frontal lobe dysfunction. We used the cognitive section of
ALS-CBS whose total score is 20
d
Inclusion Body Myositis Functional Rating Scale (IBM-FRS) consists of 10
questions about a patient’s ability to perform daily activities, such as walking,
dressing, and handling utensils. Each question was answered using a number
0–4
e
The Timed Up and Go test is a test for quantifying functional mobility and
assessing the fall risk, in which the ability to rise from a seated chair position,
walk 3 m, turn, walk back, and sit down is timed
f

Among the nine patients, five patients always used a cane, while four patients
only sometimes used it

g

Among the eleven patients, two patients always used a walker, while nine
patients only sometimes used it

h

Among the five patients, one patient always used a wheelchair, while four
patients only sometimes used it

higher than these previous scores, which also suggests
that patients with severe dementia were less likely to
attend the meeting. Although two patients were able to
be enrolled in this study with the help of their legally
authorized representatives, it is obvious that caregiver’s
support is necessary to follow up this disease, which
might cause dementia.
The distribution of muscle weakness varied from
limb-girdle pattern to distal dominant or scapuloperoneal pattern. Both questionnaire and examination
including IBMFRS/MRC scale suggested involvement
of both proximal/distal muscle weakness and predominance of the lower extremity weakness without
any muscle sparing. In a previous study, correlation
between IBMFRS and MRC scale/fatigue scale/6-min

walk test in patients with mutations of the VCP gene
was detected [27]. The results in this study also support
the idea that IBMFRS may correlate with MRC scale
in that both suggested the predominance of the lower
extremity weakness and that the IBMFRS could be useful for assessing the muscle weakness in the patients
with VCP gene mutations.
The VCP-related MSP is known to involve not only
muscle but also motor neurons and peripheral nerve,
which may make the diagnosis difficult to determine [7,
8, 14–16]. With the clinical finding of scapular winging or
distal weakness and myopathological finding of rimmed
vacuoles as well as TDP-43 immunopositive inclusions,
inclusion body myopathy is often confused with GNE
myopathy (glucosamine (UDP-N-acetyl)-2-epimerase/N
-acetylmannosamine kinase) or facioscapulohumeral
dystrophy [2]. However, compared with GNE myopathy,
which also accompany the weakness of tibialis anterior
muscles, 45% of the patients accompanied the weakness of quadriceps in this study, which tend to be spared
in GNE myopathy [28, 29]. As for the comparison with
facioscapulohumeral dystrophy, which accompany the
disproportional weakness of biceps and triceps compared
to the deltoid and forearm flexors, 64% of the patients
showed both deltoid and biceps weakness [30]. In this
study, only two patients (9%), who had severe weakness
diffusely, showed wrist flexor weakness compared with
wrist extensor weakness, which was found around 60%
of patients with inclusion body myositis [31]. Although
genetic testing is needed for the definite diagnosis of
VCP-related MSP, GNE myopathy, and facioscapulohumeral dystrophy, these differences of weakness distribution may help focusing on testing specific gene of each
disease.
In French and Spanish cohort, 29% of the patients
showed a forced vital capacity under 70% of the predicted value [2]. In a second study, the forced vital capacity as a percentage of the individual’s reference value,
was 84.44 ± 29.53 (mean ± SD, %) [27]. The results in this
study also suggest the effect on inspiratory muscles and
respiratory function should be monitored regularly. Two
patients reported cardiomyopathy who had R155H and
R191Q mutations in VCP gene. Previous reports have
identified cardiomyopathy in a patient with an R155C
mutation however the correlation between R155H/
R191Q and cardiomyopathy is first to be reported [17].
In this study, 60% of patients answered a positive QOL
while more than 80% of patients were reporting difficulties in completing specific tasks including climbing stairs
without handrail and getting up off the floor from lying
on their back without help. The gap is partly because
the task can be performed if they use handrail or they
are helped by caregivers. In addition, these results seem
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Fig. 4 Results of MRC muscle scale. The distribution of weakness on 22 patients was evaluated at the Cure VCP Disease annual conference in
2019 using the MRC scale. MRC muscle scale was converted as indicated. The dots in the figure stand for each patient’s converted score. The line
represents the mean value and the boundaries of the box represent the 5–95 percentiles. The bars represent the range. MRC Medical Research
Council

to suggest that physical inconvenience is not necessarily
linked directly to their QOL. All the participants were
supported by families or friends, which seem to contribute the positive QOL at least partly.
This study has several limitations. First, the nature
of VCP-related MSP is that as a patient progresses,
new phenotypes can emerge. For example, dementia
is a later onset feature in most patients. Therefore, the
reliability of this cross-sectional study for disease phenotypes throughout a patient’s lifetime is limited. Follow up of the patients is needed to clarify the natural
history of this disease. Second, the number of patients
who enrolled in the registry is limited. Researchers
and patients need to increase awareness of advocacy
groups and their activities. This is a significant challenge for rare diseases in which the recruitment of
single patient can influence prevalence. The Cure VCP
Disease, Inc. registry is limited as it is written in English only and biases enrollment. Future goals will be

to prepare a homepage and questionnaire written in
other languages. Third, the clinical information in the
registry is patient or caregiver reported and should be
cautiously interpreted. Performing assessments at an
annual meeting that represents patients in the registry
can help to validate patient reported findings. We are
reassured by the fact that our data so closely matches
previous cohort studies. Due to the different structure
of the patient meeting consents, which was performed
under a local institutional review board, and the structure of the registry consents, which was housed and
curated by CoRDS, we were unable to link patients in
each cohort. Therefore, the participants in each cohort
should be treated as independent cohorts that may have
an overlap of patients. For future patient conferences,
we plan to include language within the consent that will
enable us to link these participants from the registry to
a patient visit.
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Conclusion
The Cure VCP Disease Patient Registry provides the
necessary tools for remote recruitment and enrollment.
Sharing information between patients and physician/
researchers through the registry will accelerate the establishment of appropriate clinical outcome measurement
and/or biomarkers, and implementation of physical therapy and disease modifying therapies in future.
Supplementary information
Supplementary information accompanies this paper at https://doi.
org/10.1186/s13023-020-01551-0.
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